About admin

This author has not yet filled in any details.
So far admin has created 13 blog entries.

KC Investment Forum sees 17 start-ups new technologies

The Kansas City Animal Health Investment Forum is considered one of the best platforms for enabling animal health start‐ups to make a plea to investors for funding. This year's investment forum attracted even more presenting companies and investors than previous years. Animal Pharm analyst Sian Lazell attended to see which companies are seeking financial backing in 2015. This year, 17 companies gathered in the Kansas City Animal Health Corridor (KCAHC) to showcase their products and technologies to potential investors. Amongst others, some of the technologies presented included: alternatives to antibiotics; muscle atrophy and obesity treatments for pets; diagnostics; and cancer immunotherapies. The presenting companies were seeking $500,000 to $20 million of funding. Most were also on the lookout for potential licensing and strategic partnerships. Companies presenting in 2015 ELIAS Animal Health: Chief executive of the firm Tammie Wahaus said it is "working aggressively towards commercializing a cancer therapy as unique [...]

By |2019-01-15T12:33:04+00:00September 7th, 2015|Elias News, Uncategorized|0 Comments

ELIAS Animal Health Names Ronald Schultz and Noe Reyes to Scientific Advisory Board

ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable. Dr. Ron Schultz is a recognized leader on veterinary vaccines, virology and immunology. He currently serves as professor and chair of the Department of Pathobiological Sciences at the School of Veterinary Medicine at the University of Wisconsin-Madison. His primary emphasis of research focuses on the pathogenesis of viral infections in large and companion animals. He earned his doctoral degree from [...]

By |2019-01-15T12:33:04+00:00September 1st, 2015|Elias News, Uncategorized|0 Comments

ELIAS Animal Health Announces Start of Clinical Trial for ECI-OSA-11 for the Treatment of Canine Osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ECI-OSA-11, the company’s T cell-based immunotherapy for the treatment of osteosarcoma, a common form of canine cancer for which there is no cure. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. The trial will be conducted at the University of Missouri, Columbia College of Veterinary Medicine. ECI-OSA-11 is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. The patient will have surgery to remove their osteosarcoma and then will be treated with ECI-OSA-11 to eliminate cancer cells that remain following surgery. The objective of this clinical trial is to determine whether ECI-OSA-11 could replace chemotherapy as the standard [...]

By |2019-01-15T12:33:04+00:00August 4th, 2015|Elias News, Uncategorized|0 Comments